These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 4. Interleukin-1 inhibitor]. Yamasaki S; Kawakami A Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2985-90. PubMed ID: 22175142 [No Abstract] [Full Text] [Related]
26. Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation. Alejandre N; Ruiz-Palacios A; García-Aparicio AM; Blanco-Kelly F; Bermúdez S; Fernández-Sanz G; Romero FI; Aróstegui JI; Ayuso C; Jiménez-Alfaro I; Herrero-Beaumont G; Sánchez-Pernaute O Rheumatology (Oxford); 2014 Jun; 53(6):1095-9. PubMed ID: 24501247 [TBL] [Abstract][Full Text] [Related]
27. [Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with anakinra]. Klein AK; Horneff G Klin Padiatr; 2010 Jul; 222(4):266-8. PubMed ID: 20135584 [TBL] [Abstract][Full Text] [Related]
28. Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1β and rapid response to anakinra. Sabroe RA; Stokes CA; Parker LC; Higgins K; Prince LR; Sabroe I Clin Exp Dermatol; 2013 Dec; 38(8):874-7. PubMed ID: 23889084 [TBL] [Abstract][Full Text] [Related]
29. Twenty year follow up of a patient with a new de-novo NLRP3 mutation (S595G) and CINCA syndrome. Kanariou M; Dracou C; Spanou K; Möller J; Rösen-Wolff A; Schuster V; Roesler J Klin Padiatr; 2009; 221(6):379-81. PubMed ID: 19890791 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. Cassidy WM; Jones G; Williams K; Deforest A; Forghani B; Virella G; Venters C J Adolesc Health; 2005 Mar; 36(3):187-92. PubMed ID: 15737773 [TBL] [Abstract][Full Text] [Related]
31. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523 [TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months. Usonis V; Meriste S; Bakasenas V; Lutsar I; Collard F; Stoffel M; Tornieporth N Vaccine; 2005 Apr; 23(20):2602-6. PubMed ID: 15780442 [TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B; Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978 [TBL] [Abstract][Full Text] [Related]